A Serms-ospemifene For The Treatment Of Vulvovaginal Atrophy In Postmenopausal Women:A Meta-analysis

Objective:Assessment of clinical efficacy and safety of ospemifene for treatment of postmenopausal women with vulvovaginal atrophy.Method:According the request by evidence-based medicine,we did researches in a series of databases,including PubMed?Medline?Embase?CBM?Wanfang Database?CNKI for randomized controlled trials(RCTs)in relation to ospmifene 60mg/day for treatment of vulvar and vaginal atrophy(VVA).This research evaluates the risk of bias via a Cochrane systematic evaluation.The data are meta-analyzed with STATA 12.0 software.Results:This study includes 6 RCTs involving 2086 VVA patients.Each research is set up in the experimental group and the control group,the experimental group is ospemifene 60mg/ day,the control group is the placebo group.The result of RCTs shows that,compared with the control group,conditionof the experimental group are becoming better in aspects of vaginal maturation index(VMI)?vaginal PH?most bothersome symptom(MBS).And ospemifene will increase endometrial thickness,but without atypical epithelial proliferation or carcinoma.Regarding to the adverse event appeared during the treatment,increased incidence of vaginal candidiasis(mycotic infection)?vaginal discharge were seen in the experimental group.Conclusion:Compared with placebo,ospemifene significantly improved VMI,vaginal PH and MBS,and no serious adverse events occurred,which could be used as a treatment option for VVA patients.